# Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®

> **NCT04334057** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 23 (actual)

## Conditions studied

- Haemophilia A

## Interventions

- **DRUG:** Turoctocog alfa pegol

## Key facts

- **NCT ID:** NCT04334057
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-31
- **Primary completion:** 2023-11-30
- **Final completion:** 2024-01-10
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04334057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04334057, "Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04334057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*